Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Teva shares rise as company offers reassurance on former flagship drug Copaxone - MarketWatch
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Mylan sees opportunity in rival Teva's weakness - MarketWatch
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
Well, well,we'll...said he didn't know why “his team” invested which lowered the stock for months then just doubled his… | Dow jones companies, Investing, Dow jones
FDA approves first rival generic EpiPen, sending Teva shares up 6% - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Generic-drug stocks slammed by report of expanded price-fixing probe - MarketWatch
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva shares surge on corporate shake-up - MarketWatch
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Perrigo rejects Mylan, opening door for Teva - MarketWatch
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
